Wockhardt has received final approval from the FDA for marketing extended-release tablets of Lamotrigine, the generic version of GlaxoSmithKline‘s Lamictal XR.
Lamictal XR is an antiepileptic indicated as adjunctive therapy for primary generalized tonic-clonic seizures or partial onset seizures with or without secondary generalization in patients ≥13yrs of age, as well as for conversion to monotherapy in patients ≥13yrs of age with partial seizures who are receiving treatment with a single antiepileptic drug. Its precise mechanism(s) of action are unknown.
Lamotrigine Extended-Release will be available as 25mg, 50mg, 100mg, 200mg and 300mg tablets. Wockhardt is launching the product immediately.
For more information call (800) 346-6854 or visit www.wockhardt.com.